The licensed indications for topiramate (Topamax) in the UK have been broadened to ensure consistency with other European countries.
In epilepsy, Topamax monotherapy is now indicated for long-standing (as well as newly diagnosed) epilepsy and adjunctive therapy is no longer restricted to patients who are inadequately controlled on conventional first-line agents.
In migraine, treatment can now be initiated outside specialist care and no longer requires six-monthly review. In addition, prophylactic use of the drug can be considered regardless of the number and severity of migraines.
Further information: Janssen-Cilag